GlassScriptPhysician profile
Amanda Sawicki
NPI 1689240145
$5,479.37
in general payments reported to CMS, 2019-2025
37 companies · $528 in 2025
The $528 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,855 · 2022: $1,872 · 2023: $481 · 2024: $744 · 2025: $528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,753.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,752.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $949.64 | 2021-2025 | Wavewriter Alpha Prime 16 |
| Abbvie INC. | $650.99 | 2021-2024 | |
| Collegium Pharmaceutical, INC. | $533.35 | 2021-2024 | Xtampza, Belbuca |
| Amgen INC. | $407.89 | 2021-2022 | |
| Nevro Corp. | $283.29 | 2021-2023 | Senza |
| Saluda Medical Americas, INC. | $258.95 | 2024-2025 | Evoke |
| Biohaven Pharmaceuticals, INC. | $233.91 | 2021 | |
| Spr Therapeutics, INC | $227.68 | 2023-2025 | Sprint Pns System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $211.11 | 2021-2025 | Relistor |
| Relievant Medsystems, INC. | $204.81 | 2021-2022 | |
| Grt US Holding, INC. | $196.72 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $195.67 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $165.75 | 2022 | |
| Almatica Pharma LLC | $110.52 | 2021-2022 | |
| Curonix LLC | $94.05 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Foundation Fusion Solutions, LLC | $73.00 | 2024-2025 | |
| Orexo US, INC. | $70.41 | 2021 | |
| Arbor Pharmaceuticals, INC. | $69.66 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $60.37 | 2022 | |
| Si-Bone, INC. | $58.56 | 2022-2024 | |
| Nalu Medical, INC. | $57.99 | 2021 | |
| Indivior INC. | $45.16 | 2023-2025 | Sublocade |
| Protega Pharmaceutials INC | $38.69 | 2024 | Roxybond |
| Biogen, INC. | $37.50 | 2021 | |
| Ibsa Pharma INC. | $32.57 | 2024-2025 | Licart, Tirosint, Flector |
| Biodelivery Sciences International, INC. | $30.89 | 2021 | |
| Amneal Pharmaceuticals LLC | $27.25 | 2022 | |
| Mdd US Operations, LLC | $18.77 | 2021 | |
| Janssen Pharmaceuticals, INC | $18.75 | 2021 | |
| Eisai INC. | $17.23 | 2024 | |
| Sk Life Science, INC. | $15.85 | 2024 | |
| Baudax Bio INC. | $15.41 | 2022 | |
| Alnylam Pharmaceuticals INC. | $15.17 | 2023 | Onpattro |
| Kowa Pharmaceuticals America, INC. | $14.56 | 2022 | |
| International Rehabilitative Sciences, INC | $13.67 | 2022 | |
| Medtronic, INC. | $11.97 | 2022 | |
| Supernus Pharmaceuticals, INC. | $11.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Sawicki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.